The FDA rejected Eli Lilly’s request to expedite the approval process for experimental Alzheimer’s drug donanemab, but the drug’s Phase 3 trial is carrying…
Career reporter and Being Patient columnist Phil Gutis tries a next-generation new cognitive assessment, Cognivue’s AI-powered Clarity test. Here’s how it compares to the…
COVID-19: Alzheimer’s risk factor? Yes. Alzheimer’s cause? Maybe. As research continues, the link between COVID, inflammation, and neurodegeneration becomes clearer. Memory loss, confusion, cognitive…
Certain medications and health factors could increase your risk of side effects when taking LEQEMBI™ and other monoclonal antibody drugs for Alzheimer’s. Here’s what…
Phil Gutis, a career reporter and writer living with early-onset Alzheimer’s, participated in the clinical trials for the first-ever disease-modifying Alzheimer’s drug. Now, he…
A new disease-modifying Alzheimer’s drug, lecanemab — which will be distributed under the brand name Leqembi — today secured FDA approval. Today, the Food…
Will experimental drug lecanemab be safe and effective in treating Alzheimer’s? Being Patient shares what we know so far, and asks experts for direct…